{"id":3348,"date":"2021-07-20T10:38:51","date_gmt":"2021-07-20T08:38:51","guid":{"rendered":"https:\/\/www.cvs-avocats.com\/jic-sgd-pharma-pai\/"},"modified":"2025-08-22T11:03:25","modified_gmt":"2025-08-22T09:03:25","slug":"jic-sgd-pharma-pai","status":"publish","type":"post","link":"https:\/\/www.cvs-avocats.com\/fr\/jic-sgd-pharma-pai\/","title":{"rendered":"Cornet Vincent S\u00e9gurel aux c\u00f4t\u00e9s de JIC dans le cadre de la cession de SGD Pharma \u00e0 PAI Partners"},"content":{"rendered":"<div class=\"section__body\">\n<div class=\"block-strong-text\">\n<p><p><span style=\"color:black\">Cornet Vincent S&eacute;gurel a assist&eacute; China Jianyin Investment Ltd (JIC) dans le cadre de la Vendor Legal Due Diligence en vue de la cession du groupe SGD Pharma, leader mondial de l&rsquo;emballage en verre pour l&#039;industrie pharmaceutique. Dans le cadre de cette ench&egrave;re, c&rsquo;est l&#039;offre ferme du fonds d&rsquo;investissement fran&ccedil;ais PAI Partners qui a &eacute;t&eacute; retenue.<\/span><\/p>\n<\/p><\/div>\n<article class=\"article-normal\">\n<div class=\"article__entry\">\n<p>JIC &eacute;tait actionnaire majoritaire de l&#039;industriel fran&ccedil;ais&nbsp;depuis 2016. Le fonds chinois avait pris le contr&ocirc;le du verrier &agrave; l&#039;occasion de la scission du groupe Saint-Gobain Desjonqu&egrave;res.&nbsp;&nbsp;<\/p>\n<p>SGD Pharma emploie plus de 3 000 personnes dans 5 usines avec des implantations principalement en France, en Allemagne, en Inde et en Chine. Le groupe, qui produit plus de 2 millions de flacons par jour, annonce un chiffre d&#039;affaires de 347,5 M&euro; en 2020.&nbsp;<\/p>\n<\/p><\/div>\n<\/article>\n<article class=\"article-normal\">\n<div class=\"article__head\">\n<h2 class=\"article__title\">\n                    Intervenants<br \/>\n                <\/h2>\n<\/p><\/div>\n<div class=\"article__entry\">\n<p><u><strong>Conseils JIC&nbsp;<\/strong><\/u><\/p>\n<p><strong>Bredin Prat :&nbsp;<\/strong><\/p>\n<ul>\n<li>Corporate :&nbsp;Patrick Dziewolski (associ&eacute;),&nbsp;Thomas Priolet (counsel),&nbsp;Jing Wei,&nbsp;Margaux de Bourayne, Valentin Linares Cruz<\/li>\n<li>Droit fiscal&nbsp;:&nbsp;S&eacute;bastien de Mon&egrave;s (associ&eacute;),&nbsp;Franck Morhain (counsel), Pauline Belleau<\/li>\n<li>Concurrence&nbsp;:&nbsp;Yelena Trifounovitch (associ&eacute;e),&nbsp;Anne Jussiaux (counsel), Romain Verzeni<\/li>\n<li>Droit social&nbsp;:&nbsp;Laetitia Tombarello (associ&eacute;e), Emilie Gatineau<\/li>\n<li>Financement&nbsp;:&nbsp;Karine Sultan (associ&eacute;e)<\/li>\n<li>IP\/IT&nbsp;:&nbsp;Julia Apostle (counsel),&nbsp;Juliette Crouzet, Laurianne Billette<\/li>\n<\/ul>\n<p><strong>Cornet Vincent S&eacute;gurel (Vendor Legal Due Diligence)&nbsp;<\/strong><\/p>\n<ul>\n<li>Coordination <strong>:&nbsp;<\/strong>Alexis Marchand (associ&eacute;), Alexandra Thil (avocat directeur)<\/li>\n<li>Corporate :&nbsp;Alexandra Thil (avocat directeur),&nbsp;<span style=\"color:black\">G&eacute;raldine Malinge<\/span><\/li>\n<li><span style=\"color:black\">Commercial&nbsp;: Cl&eacute;mence Boissonnet (avocat directeur), Harold Bataille, Lisa Benayer, Juliette Fabry, Jacques Burghardt<\/span><\/li>\n<li><span style=\"color:black\">Financement&nbsp;: Ren&eacute;-Pierre Andlauer (associ&eacute;), Marine Cloerec, Valentin Quiviger<\/span><\/li>\n<li>Droit social : H&eacute;l&egrave;ne de Saint Germain (associ&eacute;e), Antoine Faucher, Alice Oriol<\/li>\n<li><span style=\"color:black\">Regulatory \/ Conformit&eacute;&nbsp;: C&eacute;line Rojano (avocat directeur)<\/span><\/li>\n<li><span style=\"color:black\">Droit immobilier&nbsp;: C&eacute;cile Rouquette-Terouanne (associ&eacute;), Agathe de Chazal<\/span><\/li>\n<li><span style=\"color:black\">IP\/IT\/Data&nbsp;: Fran&ccedil;ois Herpe (associ&eacute;), Caroline Drujon d&rsquo;Astros, Antoine Berdeaux<\/span><\/li>\n<\/ul>\n<p><strong>Fangda Partners <\/strong>: Chine<\/p>\n<p><strong>Hengeler Mueller&nbsp;<\/strong>: Allemagne<\/p>\n<p><strong>Khaitan &amp; Co&nbsp;<\/strong>: Inde<\/p>\n<p>&nbsp;<\/p>\n<p><u><strong>Conseils PAI Partners<\/strong><\/u><\/p>\n<p><strong>Willkie Farr &amp; Gallagher <\/strong>:<\/p>\n<ul>\n<li>Corporate : Christophe Garaud, Gr&eacute;gory de Saxc&eacute; (associ&eacute;s), Charl&egrave;ne Jaou&euml;t<\/li>\n<li>Antitrust : David Kupka, Maud Boukhris<\/li>\n<\/ul>\n<p><strong>Latham &amp; Watkins <\/strong>: Financement (UK &#8211; Londres)<\/p>\n<p><strong>Eight Advisory (Due dilligence fiscale et structuration fiscale) : <\/strong>Guillaume Rembly (associ&eacute;), K&eacute;vin Peau, Guillaume Exerjean, Priscille Baleau, Imane Sellam<\/p>\n<p>&nbsp;<\/p>\n<p><u><strong>Conseils Management<\/strong><\/u><\/p>\n<p><strong>Jeausserant Audouard : <\/strong><\/p>\n<ul>\n<li>Corporate :&nbsp;Carole Degonse (associ&eacute;e), Maxime Aps<\/li>\n<li>Droit Fiscal : Marie Frelot<\/li>\n<\/ul><\/div>\n<\/article><\/div>\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cornet Vincent S&eacute;gurel a assist&eacute; China Jianyin Investment Ltd (JIC) dans le cadre de la Vendor Legal Due Diligence en vue de la cession du groupe SGD Pharma, leader mondial de l&rsquo;emballage en verre pour l&#039;industrie pharmaceutique. Dans le cadre de cette ench&egrave;re, c&rsquo;est l&#039;offre ferme du fonds d&rsquo;investissement fran&ccedil;ais PAI Partners qui a &eacute;t&eacute; [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":3349,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":true,"footnotes":""},"categories":[16],"tags":[],"class_list":["post-3348","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communique"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/posts\/3348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/comments?post=3348"}],"version-history":[{"count":0,"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/posts\/3348\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/media\/3349"}],"wp:attachment":[{"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/media?parent=3348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/categories?post=3348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cvs-avocats.com\/fr\/wp-json\/wp\/v2\/tags?post=3348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}